Modus Therapeutics Holding AB Sustainability Reports
Modus Therapeutics Holding AB is a Swedish biotechnology company focused on developing its proprietary polysaccharide drug candidate, sevuparin, for treating diseases with high unmet medical needs such as sepsis and chronic kidney disease anemia.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 984500C147FB4EF4A471
FIGI: BBG00F36B8R0
4 reports from 2021 to 2024
